Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Authors' conclusion
Implementation of a BPA can improve infectious disease screening for patients with ARD who are started on b/tsDMARDs and has potential to improve patient safety.
Study context
- Population
- Established patients with autoimmune rheumatic disease aged ≥18 years with ≥1 visit to the rheumatology practice, October 1, 2017–March 3, 2022, starting a new b/tsDMARD
- Participants
- 257 vs 711
- Comparison
- Post-BPA implementation vs pre-BPA
- Post-BPAn = 257
- Pre-BPAn = 711reference
- Outcome
- Screening proportions for TB, HBV and HCV before a new b/tsDMARD
Methodological detailspre-post comparison, before-after, electronic health record best practice advisory
- Pre-post comparison
- Before-after
- Electronic health record best practice advisory
Main finding
As reported in the abstract
Infection screening proportions before new b/tsDMARD prescription
- Tuberculosis (TB) screening, pre-BPA to post-BPA: 66% to 82% (P ≤ 0.001)
- Hepatitis C virus (HCV) screening, pre-BPA to post-BPA: 60% to 79% (P ≤ 0.001)
- Hepatitis B core antibody screening, pre-BPA to post-BPA: 32% to 51% (P ≤ 0.001)
- Hepatitis B surface antigen screening, pre-BPA to post-BPA: 51% to 70% (P ≤ 0.001)
Original publication
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs. Arthritis Care Res (Hoboken). Published 29 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →